Showing 1 - 3 results of 3 for search 'Chelsea J. Gudgeon', query time: 0.02s Refine Results
  1. 1
    Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330

    Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330 by George S. Laszlo, Mary E. Beddoe, Colin D. Godwin, Olivia M. Bates, Chelsea J. Gudgeon, Kimberly H. Harrington, Roland B. Walter

    Published 2019-02-01
    Get full text
    Article
  2. 2
    AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

    AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. by David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter

    Published 2013-01-01
    Get full text
    Article
  3. 3
    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

    The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity by Mark F. Maurer, Katherine E. Lewis, Joseph L. Kuijper, Dan Ardourel, Chelsea J. Gudgeon, Siddarth Chandrasekaran, Sherri L. Mudri, Kayla N. Kleist, Chris Navas, Martin F. Wolfson, Mark W. Rixon, Ryan Swanson, Stacey R. Dillon, Steven D. Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T. Logan, Björn Walse, Kristine M. Swiderek, Stanford L. Peng

    Published 2022-04-01
    Get full text
    Article

Search Tools: